How to buy BeyondSpring stock

BeyondSpring Inc is a biotechnology business based in the US. BeyondSpring shares (BYSI) are listed on the NASDAQ and all prices are listed in US Dollars. BeyondSpring employs 61 staff and has a market cap (total outstanding shares value) of 0.00.

BeyondSpring share price

Use our graph to track the performance of BYSI stocks over time.

BeyondSpring shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$9.24 - $18.67
50-day moving average	$10.93
200-day moving average	$12.56
Wall St. target price	$33.25
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.90

Buy BeyondSpring shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy BeyondSpring stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of BeyondSpring Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BeyondSpring financials

Gross profit TTM	$0
Return on assets TTM	-103.49%
Return on equity TTM	-267.71%
Profit margin	0%
Book value	$0.79
Market capitalisation	$415.7 million

TTM: trailing 12 months

Shorting BeyondSpring shares

There are currently 1.2 million BeyondSpring shares held short by investors – that's known as BeyondSpring's "short interest". This figure is 0.3% down from 1.3 million last month.

There are a few different ways that this level of interest in shorting BeyondSpring shares can be evaluated.

BeyondSpring's "short interest ratio" (SIR)

BeyondSpring's "short interest ratio" (SIR) is the quantity of BeyondSpring shares currently shorted divided by the average quantity of BeyondSpring shares traded daily (recently around 211417.42808799). BeyondSpring's SIR currently stands at 5.91. In other words for every 100,000 BeyondSpring shares traded daily on the market, roughly 5910 shares are currently held short.

However BeyondSpring's short interest can also be evaluated against the total number of BeyondSpring shares, or, against the total number of tradable BeyondSpring shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BeyondSpring's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 BeyondSpring shares in existence, roughly 30 shares are currently held short) or 0.0452% of the tradable shares (for every 100,000 tradable BeyondSpring shares, roughly 45 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against BeyondSpring.

Find out more about how you can short BeyondSpring stock.

BeyondSpring share dividends

We're not expecting BeyondSpring to pay a dividend over the next 12 months.

BeyondSpring share price volatility

Over the last 12 months, BeyondSpring's shares have ranged in value from as little as $9.24 up to $18.67. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BeyondSpring's is 0.5552. This would suggest that BeyondSpring's shares are less volatile than average (for this exchange).

BeyondSpring overview

BeyondSpring Inc. , a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington.

Frequently asked questions

• What percentage of BeyondSpring is owned by insiders or institutions?

  Currently 71.545% of BeyondSpring shares are held by insiders and 16.937% by institutions.

• How many people work for BeyondSpring?

  Latest data suggests 61 work at BeyondSpring.

• When does the fiscal year end for BeyondSpring?

  BeyondSpring's fiscal year ends in December.

• Where is BeyondSpring based?

  BeyondSpring's address is: 28 Liberty Street, New York, NY, United States, 10005

• What is BeyondSpring's ISIN number?

  BeyondSpring's international securities identification number is: KYG108301006

• What is BeyondSpring's CUSIP number?

  BeyondSpring's Committee on Uniform Securities Identification Procedures number is: G10830100